*ST Sailon: Announcement on the Subsidiary Obtaining the Drug Registration Certificate for Potassium Magnesium Aspartate Injection

Securities code: 002898 Securities abbreviation: *ST Sailon Announcement number: 2026-067

Sailong Pharmaceutical Group Co., Ltd.

Announcement on the Subsidiary Obtaining the Drug Registration Certificate for Potassium Magnesium Aspartate Injection

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., a wholly-owned subsidiary of Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), has recently obtained the "Drug Registration Certificate" for Potassium Magnesium Aspartate Injection approved and issued by the State Food and Drug Administration. The relevant information is now announced as follows:

1. Basic information on drugs

Drug name: Potassium Magnesium Aspartate Injection

Dosage form: injection

Specifications: 10ml: potassium aspartate (calculated as C H KNO) 452 mg, magnesium aspartate (calculated as C H MgN O

4 6 4 8 12 2 8) 400mg

Registration classification: Chemicals Class 4

Certificate number: 2026S02017

Drug registration standard number: YBH15512026

Drug approval number: National Drug Approval Number H20264728

Drug approval number is valid until June 9, 2031

Approval conclusion: According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration, the registration is approved, and a drug registration certificate is issued. The quality standards, instructions, labels and production processes are as attached. Pharmaceutical manufacturing enterprises must comply with the requirements of pharmaceutical quality management regulations before they can produce and sell drugs.

2. Other related information about drugs

Potassium Magnesium Aspartate Injection is mainly used for the treatment of hypokalemia, ventricular arrhythmias caused by digitalis poisoning, as well as the adjuvant treatment of sequelae of myocarditis, congestive heart failure and myocardial infarction.

3. Risk warning

The approval of the above-mentioned drugs has further enriched the company's preparation varieties. The specific sales situation depends on various factors such as internal and external environmental changes, and there is a certain degree of uncertainty. The company will promptly fulfill its information disclosure obligations based on subsequent progress. Investors are advised to make prudent decisions and pay attention to preventing investment risks.

Announcement is hereby made.

The Board of Directors of Sailon Pharmaceutical Group Co., Ltd.

June 17, 2026